POLIVY-R-CHP: the first clinically meaningful improvement over a standard of care that held for 20 years1-13
Specialist views covering a range of POLARIX trial topics
Dr Hervé Tilly
University of Rouen, France
Prof. Christopher Flowers
MD, Anderson Cancer Center, University of Texas
Dr Franck Morschhauser
MD, PhD Professor of Hematology,
University of Lille
Dr Laurie H. Sehn
MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia
reduced risk of progression, relapse, or death with
POLIVY-R-CHP vs R-CHOP.1,*
That means more hope for the future, and more freedom from the threat of disease.
“The new regimen should reduce the risk of relapse and help patients avoid intensive treatments such as stem cell transplantation and chimeric antigen receptor T-cell therapy.”14
– Dr Gilles Salles, MD, PhD
Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center
Considering using
POLIVY-R-CHP for your patients?
*Stratified hazard ratio 0.73; 95% CI, 0.57–0.95; P=0.021
1L=first line; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + rituximab, cyclophosphamide, doxorubicin, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.
References: